Corvus Pharmaceuticals Inc
CRVS7.600USD
-0.220-2.81%
收盤 11/07, 16:00（美東）報價延遲15分鐘
567.58M總市值
虧損本益比TTM
關於 Corvus Pharmaceuticals Inc 公司
Corvus Pharmaceuticals, Inc. 是一家臨牀階段的生物製藥公司。該公司專注於開發 ITK 抑制劑，作爲一系列癌症和免疫疾病的免疫療法的新方法。其主要候選產品是索奎替尼，一種選擇性共價 ITK（白細胞介素 2 誘導性 T 細胞激酶）抑制劑，目前正在對患有各種複發性惡性 T 細胞淋巴瘤的患者進行多中心 1/1b 期臨牀試驗。索奎替尼旨在抑制某些惡性 T 細胞的增殖。其第二個候選產品 ciforadenant 是一種口服的腺苷 A2A 受體小分子拮抗劑，旨在通過阻斷腫瘤微環境中的免疫抑制腺苷與 A2A 受體的結合來禁用腫瘤破壞免疫系統攻擊的能力。該公司的第三個候選產品是穆帕多利單抗，一種人源化單克隆抗體，旨在與 CD73 上的特定位點發生反應。
Corvus Pharmaceuticals Inc簡介
公司代碼CRVS
公司名稱Corvus Pharmaceuticals Inc
上市日期Mar 23, 2016
CEODr. Richard A. Miller, M.D.
員工數量31
證券類型Ordinary Share
年結日Mar 23
公司地址863 Mitten Rd Ste 102
城市BURLINGAME
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編94010-1311
電話16509004520
網址https://www.corvuspharma.com/
公司代碼CRVS
上市日期Mar 23, 2016
CEODr. Richard A. Miller, M.D.
Corvus Pharmaceuticals Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Richard A. Miller, M.D.
Dr. Richard A. Miller, M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
2.32M
+31.66%
Mr. Leiv Lea
Mr. Leiv Lea
Chief Financial Officer
Chief Financial Officer
282.44K
--
Dr. Linda S. Grais, M.D., J.D.
Dr. Linda S. Grais, M.D., J.D.
Independent Director
Independent Director
10.00K
--
Mr. Scott W. Morrison, CPA
Mr. Scott W. Morrison, CPA
Independent Director
Independent Director
--
--
Mr. Jeffrey S. Arcara
Mr. Jeffrey S. Arcara
Senior Vice President, Chief Business Officer
Senior Vice President, Chief Business Officer
--
--
Dr. Peter A. Thompson, M.D.
Dr. Peter A. Thompson, M.D.
Independent Director
Independent Director
--
--
Mr. Ian T. Clark
Mr. Ian T. Clark
Independent Director
Independent Director
--
--
Dr. William B. Jones, Ph.D.
Dr. William B. Jones, Ph.D.
Senior Vice President - Pharmaceutical Development
Senior Vice President - Pharmaceutical Development
--
--
Mr. Richard van Den Broek
Mr. Richard van Den Broek
Independent Director
Independent Director
--
--
Mr. David Moore
Mr. David Moore
Director
Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Richard A. Miller, M.D.
Dr. Richard A. Miller, M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
2.32M
+31.66%
Mr. Leiv Lea
Mr. Leiv Lea
Chief Financial Officer
Chief Financial Officer
282.44K
--
Dr. Linda S. Grais, M.D., J.D.
Dr. Linda S. Grais, M.D., J.D.
Independent Director
Independent Director
10.00K
--
Mr. Scott W. Morrison, CPA
Mr. Scott W. Morrison, CPA
Independent Director
Independent Director
--
--
Mr. Jeffrey S. Arcara
Mr. Jeffrey S. Arcara
Senior Vice President, Chief Business Officer
Senior Vice President, Chief Business Officer
--
--
Dr. Peter A. Thompson, M.D.
Dr. Peter A. Thompson, M.D.
Independent Director
Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 8月19日 週二
更新時間: 8月19日 週二
持股股東
股東類型
持股股東
持股股東
佔比
OrbiMed Advisors, LLC
9.59%
Point72 Asset Management, L.P.
9.43%
BlackRock Institutional Trust Company, N.A.
4.84%
The Vanguard Group, Inc.
4.65%
Adams Street Partners, LLC
4.39%
其他
67.10%
持股股東
持股股東
佔比
OrbiMed Advisors, LLC
9.59%
Point72 Asset Management, L.P.
9.43%
BlackRock Institutional Trust Company, N.A.
4.84%
The Vanguard Group, Inc.
4.65%
Adams Street Partners, LLC
4.39%
其他
67.10%
股東類型
持股股東
佔比
Private Equity
18.22%
Investment Advisor
13.86%
Hedge Fund
11.23%
Investment Advisor/Hedge Fund
8.66%
Individual Investor
3.95%
Venture Capital
2.99%
Research Firm
1.01%
Pension Fund
0.20%
Bank and Trust
0.09%
其他
39.79%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
186
42.32M
56.66%
+2.43M
2025Q2
154
41.04M
53.29%
-590.66K
2025Q1
158
41.01M
55.15%
-1.27M
2024Q4
137
42.04M
65.42%
+8.08M
2024Q3
112
32.95M
52.86%
+765.53K
2024Q2
108
30.52M
48.98%
-5.02M
2024Q1
116
20.23M
41.14%
-8.66M
2023Q4
119
21.51M
43.96%
-7.95M
2023Q3
129
21.52M
44.20%
-7.79M
2023Q2
132
21.81M
46.84%
-8.41M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
OrbiMed Advisors, LLC
7.17M
9.62%
+221.35K
+3.19%
Jun 30, 2025
Point72 Asset Management, L.P.
7.04M
9.45%
+4.25M
+152.63%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.62M
4.85%
+2.65M
+274.72%
Jun 30, 2025
The Vanguard Group, Inc.
3.28M
4.4%
+786.56K
+31.54%
Jun 30, 2025
Adams Street Partners, LLC
3.28M
4.4%
--
--
Jun 30, 2025
RTW Investments L.P.
2.68M
3.6%
--
--
Jun 30, 2025
Miller (Richard A)
2.32M
3.12%
+559.07K
+31.66%
May 07, 2025
Vivo Capital, LLC
2.23M
3%
--
--
Jun 30, 2025
Foresite Capital Management, LLC
1.73M
2.32%
+150.00K
+9.49%
Jun 30, 2025
Perceptive Advisors LLC
1.44M
1.93%
+1.44M
--
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月6日 週四
更新時間: 11月6日 週四
機構名稱
佔比
Virtus LifeSci Biotech Clinical Trials ETF
1.25%
Invesco NASDAQ Future Gen 200 ETF
0.62%
Tema Oncology ETF
0.55%
iShares Micro-Cap ETF
0.08%
ProShares Ultra Nasdaq Biotechnology
0.06%
Invesco Nasdaq Biotechnology ETF
0.05%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.05%
iShares Biotechnology ETF
0.04%
iShares Russell 2000 Growth ETF
0.03%
Proshares Ultra Russell 2000
0.02%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
佔比1.25%
Invesco NASDAQ Future Gen 200 ETF
佔比0.62%
Tema Oncology ETF
佔比0.55%
iShares Micro-Cap ETF
佔比0.08%
ProShares Ultra Nasdaq Biotechnology
佔比0.06%
Invesco Nasdaq Biotechnology ETF
佔比0.05%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
佔比0.05%
iShares Biotechnology ETF
佔比0.04%
iShares Russell 2000 Growth ETF
佔比0.03%
Proshares Ultra Russell 2000
佔比0.02%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
